Offering whole genome sequencing (WGS) to women with breast cancer could open up treatment options and guide clinical trial access for thousands of additional patients each year, suggests research led by scientists at the University of Cambridge in the U.K.

“Our work shows that WGS offers the ability to distinguish clinically important subsets of breast cancer patients, including patients that could respond more effectively to targeted therapeutics from those at risk of premature mortality, and may even help to identify patients for that are genuinely at low-risk and likely to be fully cured if treated appropriately,” said senior author Professor Serena Nik-Zainal, MD, PhD, from the department of Genomic Medicine and Early Cancer Institute at the University of Cambridge.

In 2022, there w

See Full Page